Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KCNH1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNH1 Extracellular Loop Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View KCNH1 Products |
| Gene Delivery | KCNH1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Optimized for electrophysiology and flow cytometry. |
View KCNH1 Products |
| Benchmark Ab | Anti-KCNH1 Recombinant Antibody Recombinant positive control for surface expression and functional blocking validation. |
View KCNH1 Products |
| Validator | KCNH1 siRNA Set For knockdown verification in target-positive cancer cell lines. |
View KCNH1 Products |
| Related Target A | KCNH2 (hERG) Critical counter-screening target to ensure cardiac safety and selectivity. |
View KCNH2 Products |
| Related Target B | KCNH5 (EAG2) Subfamily homologue for specificity profiling in central nervous system safety assays. |
View KCNH5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Targets | Lentivirus-mediated stable cell line development preserves native 6-transmembrane folds. |
| hERG (KCNH2) Cross-reactivity & Cardiotoxicity Screening | Sequence-verified KCNH2 lentiviral tools enable parallel counter-screening assays. |
| Lack of Validated Positive Controls | Recombinant sequence-matched benchmark antibodies available for functional assay calibration. |
| Assay Background Noise & Off-target Effects | High-specificity siRNA validation sets confirm target-dependent signaling and phenotype rescue. |
Live KCNH1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNH1 (EAG1) therapeutics is intensifying, with major players shifting focus from traditional small-molecule blockers to targeted biologics and antibody-drug conjugates (ADCs). Because KCNH1 is virtually absent in healthy peripheral tissues but highly overexpressed in various solid tumors (including breast, colon, and prostate cancers), it serves as an ideal tumor-specific antigen. As first-generation non-selective channel blockers face limitations due to cardiotoxicity, the next wave of R&D is targeting extracellular loops with highly selective monoclonal antibodies and cell-based functional assays to modulate channel gating without cross-reacting with KCNH2 (hERG).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biotech Startups | Breast Cancer, Ovarian Cancer | Surface binding and internalization assays (Need KCNH1 overexpressing stable cell lines). |
| Small Molecule Inhibitors | Pharmaceutical Companies | Solid Tumors, Gliomas | Selectivity profiling against KCNH2/hERG (Need KCNH1 and KCNH2 stable cell line panels). |
| CAR-T / Cell Therapies | Cell Therapy Developers | Refractory Solid Tumors | Target density quantification and cytolytic assays (Need stable target-expressing target cells). |